RiboBio's First-in-Class siRNA Therapy RBD7007 for IgA Nephropathy Receives EU Clinical Trial Approval
Ribo Life Science
Small Nucleic Acid Drug Developer
Recently, Suzhou Ribo Life Science Co., Ltd. (referred to as "Ribo Life Science") independently developed the siRNA drug RBD7007 targeting C5, which has obtained EU clinical trial approval and will initiate its first human clinical trial in Sweden.
C5, as one of the key components of the complement system, plays a role in innate immunity, participates in immune protection of the body, and modulates adaptive immune responses. The development and progression of various immune and complement-related diseases, including IgA nephropathy and other complement immune-related conditions, have been confirmed to be associated with the abnormal activation of C5. However, currently approved antibody drugs targeting C5 have issues with short half-lives and limited durations of sustained efficacy.
RBD7007 is a product of Ribo Life Science based on RIBO-GalSTAR.TMRBD7007, an siRNA drug independently developed by the liver-targeting technology platform targeting C5, inhibits the expression of the C5 protein and blocks the activation of the complement pathway to achieve its therapeutic effect on complement-mediated diseases. Preclinical trial data show that RBD7007 has a lasting and potent inhibitory effect on complement pathway activation while demonstrating good safety, with the expectation of bringing significant therapeutic benefits to patients with IgA nephropathy and other complement-mediated diseases.
This Phase I clinical trial is a randomized, double-blind, placebo-controlled Phase I study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD7007 in healthy subjects with single-dose escalation and multiple-dose escalation. The results of the trial will support dose selection and dosing regimens for future Phase II clinical trials in patients.
Ribo Life Science has multiple products based on RIBO-GalSTARTMRibo Life Science has advanced its siRNA drugs into clinical stages, covering disease areas including cardiometabolic disorders, liver diseases, and immune-related conditions. Ribo Life Science will continue to deepen its expertise and provide patients with more innovative siRNA drugs.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (referred to as "Ribo Life Science") is an innovative R&D company dedicated to developing RNA interference (RNAi) drugs and is a major pioneer and leader in China’s small nucleic acid technology and small nucleic acid pharmaceuticals industry. The company's headquarters is located in Kunshan, Jiangsu, with R&D centers in Beijing and Gothenburg, Sweden.
Ribo Life Science benchmarks the innovative frontier of international small nucleic acid technology, committing to the iterative research and development of small nucleic acid chemical modification and drug delivery technology. It has established a self-controlled, fully integrated small nucleic acid drug R&D platform that supports the entire lifecycle of small nucleic acid drugs from early-stage R&D to industrialization. Its self-developed GalNAc small nucleic acid drug delivery technology platform is named RIBO-GalSTAR.TMWith international competitive level, highly specific liver targeting, and features of high efficiency and long duration, positive progress has also been made in the field of extrahepatic delivery, further supporting the company's global development strategy based on innovation and differentiation.